In vivo virulence of MHC-adapted AIDS virus serially-passaged through MHC-mismatched hosts

PLoS Pathog. 2017 Sep 20;13(9):e1006638. doi: 10.1371/journal.ppat.1006638. eCollection 2017 Sep.

Abstract

CD8+ T-cell responses exert strong suppressive pressure on HIV replication and select for viral escape mutations. Some of these major histocompatibility complex class I (MHC-I)-associated mutations result in reduction of in vitro viral replicative capacity. While these mutations can revert after viral transmission to MHC-I-disparate hosts, recent studies have suggested that these MHC-I-associated mutations accumulate in populations and make viruses less pathogenic in vitro. Here, we directly show an increase in the in vivo virulence of an MHC-I-adapted virus serially-passaged through MHC-I-mismatched hosts in a macaque AIDS model despite a reduction in in vitro viral fitness. The first passage simian immunodeficiency virus (1pSIV) obtained 1 year after SIVmac239 infection in a macaque possessing a protective MHC-I haplotype 90-120-Ia was transmitted into 90-120-Ia- macaques, whose plasma 1 year post-infection was transmitted into other 90-120-Ia- macaques to obtain the third passage SIV (3pSIV). Most of the 90-120-Ia-associated mutations selected in 1pSIV did not revert even in 3pSIV. 3pSIV showed lower in vitro viral fitness but induced persistent viremia in 90-120-Ia- macaques. Remarkably, 3pSIV infection in 90-120-Ia+ macaques resulted in significantly higher viral loads and reduced survival compared to wild-type SIVmac239. These results indicate that MHC-I-adapted SIVs serially-transmitted through MHC-I-mismatched hosts can have higher virulence in MHC-I-matched hosts despite their lower in vitro viral fitness. This study suggests that multiply-passaged HIVs could result in loss of HIV-specific CD8+ T cell responses in human populations and the in vivo pathogenic potential of these escaped viruses may be enhanced.

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / immunology
  • Histocompatibility Antigens Class I / genetics*
  • Immune Evasion / genetics
  • Immune Evasion / immunology*
  • Macaca mulatta
  • Simian Immunodeficiency Virus / immunology*
  • Simian Immunodeficiency Virus / pathogenicity*
  • Virulence

Substances

  • Histocompatibility Antigens Class I

Grants and funding

This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology in Japan (MEXT: http://www.mext.go.jp/english/) ([JSPS] KAKENHI Grants 15H04737, 15H01271, 88000500), grants-in-aid from the Ministry of Health, Labor and Welfare in Japan (MHLW: http://www.mhlw.go.jp/english/index.html) (H24-AIDS-006), and Research Programs on HIV/AIDS, Emerging and Re-emerging Infectious Diseases, an Integrated Database of Clinical and Genomic Information, and Global Health Issues from Japan Agency for Medical Research and Development (AMED: http://www.amed.go.jp/en/) (17fk0410301j0003, 17fk0410203j0202; 17fk0108124j0001, 17kk0205011j0002, 17jk0210002h0001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.